Evaluation of the Effect of Vitreous Composition Determined by Ultrasound and Optical Coherence Tomography (OCT) on Ranibizumab Therapy (PVD)

This study has been completed.
Genentech, Inc.
Information provided by (Responsible Party):
Michael T. Trese, M.D., Vision Research Foundation
ClinicalTrials.gov Identifier:
First received: December 2, 2010
Last updated: June 26, 2012
Last verified: June 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: October 2010
  Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)